Abstract
The effects of cyclical treatment with estrone sulfate (0.3, 0.625, or 1.25 mg), plus calcium carbonate, on spinal trabecular bone density were compared with placebo in 120 postmenopausal women in this 2-year, multicenter, doubleblind study. While the placebo and 0.3-mg treatment groups lost bone density (-3.6% and -5.1%), the 0.625- and 1.25-mg treatment groups experienced no significant change from baseline at 24 months (-0.8% and +0.7%). The 1.25-mg treatment group was significantly different from the placebo group at 12,18, and 24 months. Although the 0.625-mg treatment group was significantly different from the placebo group only at 18 months, the data suggest that 0.625 and 1.25 mg of estrone sulfate had different effects than placebo and 0.3 mg of estrone sulfate and, given with supplemental calcium, are effective doses for the prevention of spinal bone loss.
| Original language | English |
|---|---|
| Pages (from-to) | 1980-1984 |
| Number of pages | 5 |
| Journal | Archives of Internal Medicine |
| Volume | 151 |
| Issue number | 10 |
| DOIs | |
| State | Published - 1991 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
Cite this
The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women. / Harris, Steven T.; Genant, Harry K.; Baylink, David J.; Gallagher, John Christopher G.; Karp, Sherry Katz; Mcconnell, Maureen A.; Green, Elizabeth M.; Stoll, Ralph W.
In: Archives of Internal Medicine, Vol. 151, No. 10, 1991, p. 1980-1984.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Effects of Estrone (Ogen) on Spinal Bone Density of Postmenopausal Women
AU - Harris, Steven T.
AU - Genant, Harry K.
AU - Baylink, David J.
AU - Gallagher, John Christopher G.
AU - Karp, Sherry Katz
AU - Mcconnell, Maureen A.
AU - Green, Elizabeth M.
AU - Stoll, Ralph W.
PY - 1991
Y1 - 1991
N2 - The effects of cyclical treatment with estrone sulfate (0.3, 0.625, or 1.25 mg), plus calcium carbonate, on spinal trabecular bone density were compared with placebo in 120 postmenopausal women in this 2-year, multicenter, doubleblind study. While the placebo and 0.3-mg treatment groups lost bone density (-3.6% and -5.1%), the 0.625- and 1.25-mg treatment groups experienced no significant change from baseline at 24 months (-0.8% and +0.7%). The 1.25-mg treatment group was significantly different from the placebo group at 12,18, and 24 months. Although the 0.625-mg treatment group was significantly different from the placebo group only at 18 months, the data suggest that 0.625 and 1.25 mg of estrone sulfate had different effects than placebo and 0.3 mg of estrone sulfate and, given with supplemental calcium, are effective doses for the prevention of spinal bone loss.
AB - The effects of cyclical treatment with estrone sulfate (0.3, 0.625, or 1.25 mg), plus calcium carbonate, on spinal trabecular bone density were compared with placebo in 120 postmenopausal women in this 2-year, multicenter, doubleblind study. While the placebo and 0.3-mg treatment groups lost bone density (-3.6% and -5.1%), the 0.625- and 1.25-mg treatment groups experienced no significant change from baseline at 24 months (-0.8% and +0.7%). The 1.25-mg treatment group was significantly different from the placebo group at 12,18, and 24 months. Although the 0.625-mg treatment group was significantly different from the placebo group only at 18 months, the data suggest that 0.625 and 1.25 mg of estrone sulfate had different effects than placebo and 0.3 mg of estrone sulfate and, given with supplemental calcium, are effective doses for the prevention of spinal bone loss.
UR - http://www.scopus.com/inward/record.url?scp=0025954637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025954637&partnerID=8YFLogxK
U2 - 10.1001/archinte.1991.00400100060010
DO - 10.1001/archinte.1991.00400100060010
M3 - Article
VL - 151
SP - 1980
EP - 1984
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
SN - 2168-6106
IS - 10
ER -